Life sciences business OptiBiotix Health plc (AIM: OPTI) has launched its SlimBiome-based GoFigure products on Amazon India, targeting the world's most populous nation and its growing consumer base.
India, with obesity rates at 40.3% and projected to have the largest medium-to-high income population by 2035, offers significant opportunities for weight management products.
GoFigure products will also remain available through Apollo Pharmacies, both in-store and online, as part of a multi-channel strategy to drive growth in high-potential markets. The Amazon launch coincides with a rebranding effort featuring more vibrant packaging and prominent Fossence branding, leveraging consumer trust in Tata's proprietary ingredient.
OptiBiotix, founded in 2012, develops microbiome-modifying compounds addressing obesity, cardiovascular health and diabetes. Its partnerships with over 20 global food and healthcare companies further enhance its position in the wellness market.
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption